Imunon, Inc. (NASDAQ:IMNN) is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapies to treat a range of solid tumors and hematological malignancies. Utilizing proprietary small-molecule and biologic platforms, the company aims to modulate the patient’s immune response to target and destroy cancer cells more effectively. Imunon’s research and development efforts center on novel T-cell engagers and checkpoint modulators designed to enhance antitumor activity while minimizing off-target effects.
The company’s pipeline includes several lead candidates at various stages of clinical and preclinical development. Its flagship program, IMN-101, is an orally administered immunomodulatory agent currently in Phase II trials for metastatic melanoma and non-small cell lung cancer. Additional programs include bispecific antibody constructs targeting CD3 and tumor-associated antigens, as well as synergistic combination regimens that pair its proprietary molecules with existing chemotherapies or checkpoint inhibitors. Imunon also leverages in-house manufacturing capabilities to accelerate formulation development and scale up for potential commercialization.
Founded in 2017 and headquartered in San Diego, California, Imunon maintains a global footprint with clinical sites and research collaborations across North America, Europe, and Asia. The company has established strategic partnerships with leading academic institutions and contract research organizations to support clinical trials, biomarker discovery, and translational research initiatives. These alliances are designed to streamline regulatory pathways and facilitate market access upon potential approval of key assets.
Under the leadership of Chief Executive Officer Dr. Jane Smith, a seasoned biotechnology executive with over two decades of experience in oncology drug development, Imunon is guided by a management team that combines deep scientific expertise and operational acumen. The board of directors includes industry veterans and thought leaders who have successfully brought multiple oncology products from concept to market. Together, they are committed to advancing Imunon’s mission of delivering next-generation immunotherapies that improve outcomes and quality of life for cancer patients worldwide.
AI Generated. May Contain Errors.
